title: GUTI: a new antigen in the Cromer blood group system.
abstract: BACKGROUND
  The Cromer blood group system consists of seven high-incidence and three low-incidence antigens carried on decay-accelerating factor (DAF). This report describes the identification and characterization of a new Cromer high-incidence antigen, named GUTI.
  
  
  METHODS
  RT-PCR and sequence analysis were performed on cDNA prepared from a Chilean donor whose serum contained the alloantibody (anti-GUTI). Based on the observed point mutation, a PCR-RFLP assay using MaeII was developed. To map the epitope, DAF-deletion mutants were tested by immunoblotting with anti-GUTI.
  
  
  RESULTS
  Sequence analysis revealed a substitution of 719G>A in DAF in the proband. The proband's parents and two daughters were heterozygotes for 719G>A, one sister whose RBCs typed GUTI- was homozygous for 719A, and one sister had the wild-type DAF (719G). Seven additional heterozygote samples were identified among 214 Chileans. No heterozygotes were found in 197 New York donors. Analysis using DAF-deletion mutants showed the antigenic determinant to be within short consensus repeat (SCR) 4.
  
  
  CONCLUSIONS
  This study describes a novel high- incidence antigen (GUTI) in the Cromer blood group system characterized by the amino acid arginine at position 206 in SCR4 of DAF. The GUTI-negative proband has a substitution mutation that predicts for histidine at this position.
authors.affiliation: Immunohematology Laboratory, New York Blood Center, New York, NY 10021, USA.
authors.forename: Jill R
authors.initials: JR
authors.lastname: Storry
authors.forename: Laima
authors.initials: L
authors.lastname: Sausais
authors.forename: Kim
authors.initials: K
authors.lastname: Hue-Roye
authors.forename: Flora
authors.initials: F
authors.lastname: Mudiwa
authors.forename: Zennie
authors.initials: Z
authors.lastname: Ferrer
authors.forename: Morris A
authors.initials: MA
authors.lastname: Blajchman
authors.forename: Douglas M
authors.initials: DM
authors.lastname: Lublin
authors.forename: Bei-Wen
authors.initials: BW
authors.lastname: Ma
authors.forename: Juan F
authors.initials: JF
authors.lastname: Miquel
authors.forename: Flavio
authors.initials: F
authors.lastname: Nervi
authors.forename: Jaime
authors.initials: J
authors.lastname: Pereira
authors.forename: Marion E
authors.initials: ME
authors.lastname: Reid
mesh_terms: D000328:Adult; D001789:Blood Group Antigens / Q000276:immunology*; D018958:CD55 Antigens / Q000276:immunology*; D002677:Chile; D018076:DNA, Complementary / Q000737:chemistry; D015252:Deoxyribonucleases, Type II Site-Specific; D004910:Erythrocyte Membrane / Q000737:chemistry / Q000276:immunology; D017353:Gene Deletion; D006801:Humans; D007518:Isoantibodies / Q000097:blood; D007519:Isoantigens / Q000737:chemistry / Q000235:genetics* / Q000276:immunology; D008297:Male; D009154:Mutation; D012150:Polymorphism, Restriction Fragment Length; D020133:Reverse Transcriptase Polymerase Chain Reaction; D017422:Sequence Analysis, DNA
chemical_list: D001789:Blood Group Antigens; D018958:CD55 Antigens; D018076:DNA, Complementary; C473225:GUTI antigen, human; D007518:Isoantibodies; D007519:Isoantigens; C040837:endodeoxyribonuclease MaeII; D015252:Deoxyribonucleases, Type II Site-Specific